허가사항 범위(파킨슨 증후군의 급성 악화 시에 무운동성 발작의 초기 및 단기 치료) 내에서 투여 시 요양급여를 인정함.
■ 고시 개정 고시번호(시행일자)
고시 제2018-253호(2018.12.1.)
■ 고시 개정 사유
국내ㆍ외 허가사항, 교과서, 임상진료지침, 임상연구문헌, 관련 학회의견 등을 참조하여, 최대 인정 기간을 삭제하고 허가사항 내에서 급여 인정함.
■ 관련문헌 등
· Harrison's Principles of Internal Medicine, 20e , 2018 > Chapter 427: Parkinson’s Disease
· Goldman-Cecil Medicine Twenty-Fifth Edition, 2016 > Chapter409. parkinsonism
· NICE (Parkinson’s disease in adults , Published: 19 July 2017) > 1.3 Pharmacological management of motor symptoms
· Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. The National Collaborating Centre for Chronic Conditions(NCC-CC, UK).2006. > 7. Symptomatic pharmacological therapy in Parkinson’s disease
· SIGN (Scottish Intercollegiate Guidelines Network), Diagnosis and pharmacological management of Parkinson’s disease, A national clinical guideline, January 2010 > 5 Pharmacological management
· Lee JY, et al, Intravenous amantadine on freezing of gait in Parkinson's disease: a randomized controlled trial. J Neurol. 2013 Dec;260(12):3030-8. doi: 10.1007/s00415-013-7108-7. Epub 2013 Sep 22.
· Bostantjopoulou S, et al, Amantadine sulfate infusion effect on N30 somatosensory evoked potentials in Parkinson's disease. Clin Neuropharmacol. 2002 Mar-Apr;25(2):115-8.
· Brenner M, et al, Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations. J Neurol. 1989 Mar;236(3):153-6.